BeyondSpring(BYSI) - 2025 Q4 - Annual Results

Financial Performance - BeyondSpring reported a net loss of $14.2 million for the year ended December 31, 2025, compared to a net loss of $16.7 million in 2024, reflecting a decrease of 15%[26] - Net loss attributable to BeyondSpring Inc. was $11.123 million, compared to a loss of $1.006 million in the previous period[27] - Basic and diluted loss per share was $0.28, up from $0.02 in the prior year[27] - Comprehensive loss attributable to BeyondSpring Inc. was $10.681 million, compared to $1.740 million in the previous period[27] - Continuing operations reported a comprehensive loss of $15.966 million, slightly higher than $15.471 million from the previous year[27] - Weighted-average shares outstanding decreased to 39,733,191 from 40,406,347[27] Research and Development - Research and development expenses increased to $4.4 million in 2025 from $2.6 million in 2024, driven by higher costs associated with drug manufacturing and clinical trials[20] - Plinabulin demonstrated a median overall survival improvement of 2.5 months compared to docetaxel in the DUBLIN-3 study, with a hazard ratio of 0.72 (p=0.0078)[13] - The DUBLIN-4 confirmatory trial for Plinabulin is planned to focus on EGFR wild-type NSCLC patients who have progressed on immune checkpoint inhibitors[10] - The overall response rate (ORR) for Plinabulin combined with pembrolizumab and docetaxel in a Phase 2 study was reported at 18.2%[14] - The company reported a favorable safety profile for Plinabulin, reducing grade 4 neutropenia from over 30% to 5% in clinical studies[13] - SEED Therapeutics initiated its first clinical trial following IND clearance in both the U.S. and China, marking a critical milestone for the company[4] Financial Position - The company completed a $30 million Series A-3 financing to strengthen its financial position and support ongoing clinical programs[20] - As of December 31, 2025, cash, cash equivalents, and short-term investments totaled $12.6 million, a significant increase from $2.9 million in 2024[20] - Current assets decreased to $20.9 million in 2025 from $28.6 million in 2024, primarily due to the reclassification of SEED's operations as discontinued[23] Foreign Currency Adjustments - Foreign currency translation adjustment from continuing operations showed a gain of $710, contrasting with a loss of $1,147 in the prior year[27] - Foreign currency translation adjustment from discontinued operations reported a gain of $17, compared to a loss of $107 previously[27] Noncontrolling Interests - Net loss attributable to noncontrolling interests from discontinued operations was $5.182 million, down from $12.969 million[27] - Net loss attributable to noncontrolling interests from continuing operations was $0.388 million, compared to $0.242 million in the previous period[27] - The company experienced a significant increase in comprehensive loss attributable to noncontrolling interests from discontinued operations, which was $5.154 million compared to $13.076 million last year[27]